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Abstract Using poly(MAA-PEGMA)-coated superparamagnetic nanoparticles (PMNPs) as carrier, a rapid
and sensitive immunoassay for quantitative determination of interleukin-6 (IL-6) has been developed for
the first time. This protocol involved a sandwich format in which the IL-6 in samples was first captured
by the primary monoclonal antibody (mAb) immobilized on the surface of PMNPs, and then recognized
by the second monoclonal antibody labeled with horseradish peroxidase (HRP-mAb). The HRP-mAb
dilution and immunoreaction time were examined and optimized. The linear range for IL-6 assay was
3.2–1000 pg mL−1, and the Limit Of Detection (LOD) was 1.0 pg mL−1. The developed immunoassay
method showed high precision, high sensitivity, acceptable recovery and relatively good reliability, and
could be used to detect serum IL-6 levels with consistent results in comparison with those obtained by
the Enzyme-Linked Immunosorbent Assay (ELISA) method.
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Interleukin-6 (IL-6), a member of a family of structurally re-
lated cytokines, has a range of biological activities in the reg-
ulation of immune response, inflammation, hemopoiesis and
oncogenesis. It is normally tightly regulated and expressed at
low levels, but increases under various conditions characterized
by inflammation, such as sepsis and endotoxemia, and in re-
sponse to proinflammatory cytokines [1]. IL-6 has been shown
to be associated with cancer development, and Chung et al.
have detected the serum IL-6 levels in colorectal cancer patients
(median value: 11.89 pg ml−1, range 0–440.64 pg ml−1) that
were significantly higher than those in normal subjects (me-
dian value: 3.41 pg ml−1, range 0–9.12 pg ml−1, P < 0.01) [2].
Overproduction of IL-6 is involved in the pathology of inflam-
matory diseases including rheumatoid arthritis, Castleman’s
disease, bladder cancer and liver damage [3]. Therefore, not
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concentration allows the study of the immunological network
and its interaction with the pathogenesis of disease develop-
ment [4]. Nowadays, several methods for IL-6 determination
based on ELISA are proposed, including chemiluminescence im-
munoassay [5], the flow immunoassay system (FIA) and so on.
In order to enhance the sensitivity of IL-6 determination, the use
of superparamagnetic nanoparticles, as a carrier, was one of the
most attractive methods.
In our group, we have synthesized poly(MAA-PEGMA)-
coated superparamagnetic nanoparticles (PMNPs) and other
polymer-coated superparamagnetic nanoparticles, via photo-
chemical polymerization [6–8]. The aim of our present work
was to develop a new magnetic affinity immunoassay based
on PMNPs for the determination of IL-6. The performance cri-
teria of this method, with specifically adapted characteristics,
are discussed in the following section.
2. Experimental
2.1. Reagents and instrumentation
Poly(MAA-PEGMA)-coated superparamagnetic nanoparti-
cles (PMNPs) (d ≈ 54 nm) were synthesized in our Lab [8].
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was
supplied by the Shanghai Chemical Reagents Corporation
(China). IL-6 standard, a pair of anti-IL-6 monoclonal antibod-
ies (one of which was HRP-labeled) and the conventional ELISA
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Tech Co., Ltd. China. Bovine SerumAlbumin (BSA) and TMB per-
oxidase substrate were purchased from the DingGuo Company,
China, and Tween-20was a product of Shanghai Sangon Biolog-
ical Engineering Technology & Services Co., Ltd. China. Serum
samples were collected from DeZhou Peoples’ Hospital, China.
All other chemicals were of analytical grade.
2.2. Immobilization of mAb on PMNPs
PMNPs (1.0 mg) was washed three times with MES buffer
(pH 4.5), then dispersed in 1.0 mL of EDC solution (0.4 mol L−1
in MES). The mixture was incubated for 10 min at room
temperature. The activated/active PMNPs were magnetically
separated and mixed with 20 µg of mAb in 1.0 mL of PBS
(0.1 mol L−1, pH7.4). The mixture was shaken for 2 h at
37 °C. The mAb-PMNPs were collected magnetically, and
washed three times with washing buffer (PBS with 0.05%
Tween-20, v/v, PBS-T). The absorbance at 280 nm of pre-
and post- immobilization antibody solutions and the washing
bufferwas determinedwith aUV spectrophotometer (UV-1800,
Shimadzu), to calculate the amount of immobilized mAb. Then,
1.0 mL of BSA (3% in PBS) was added into the mAb-PMNPs and
the mixture was incubated for 2 h at 37 °C, with shaking, to
block the remaining free sites on the PMNPs surface. Finally, the
mAb-PMNPs were washed with PBS-T three times, suspended
in 1.0 mL of PBS (containing 0.5% BSA) and then stored at 4 °C.
2.3. Enzyme-linked immunoassay procedure
20 µL of mAb-PMNPs and 100 µL of IL-6 standard, which
was serially diluted to a range from 1000 to 3.2 pg mL−1, were
incubated at 37 °C for 20 min to form the Ag-mAb-PMNPs
complex. The complex was washed three times with PBS-T,
using a magnetic separator. Then, 50 µL of HRP-mAb (diluted
in PBS-T containing 1% BSA) was added, and the mixture
was incubated for 20 min, as the first incubation. Unbound
HRP-mAb was removed by washing three times with PBS-T,
and then 200 µL of TMB solution was introduced. After 5-
min incubation at 37 °C, 100 µL of 2 M H2SO4 was added
to terminate the reaction. Following magnetic separation, the
colored supernatant was transferred to a micro-titer plate, and
the absorbance at 450 nm (A450) was read. The conventional
ELISA kit, which uses the same couple of mAb as the PMNPs-
based method, was operated according to instructions. Briefly,
the serum samples or IL-6 standard were added and incubated
at 37 °C for 40min. The platewaswashedwithWash Buffer five
times, HRP-mAbwas added and incubated for 40 min, and then
the reaction was stopped and the absorbance was read.
3. Results and discussion
3.1. Immobilization of mAb on PMNPs
The synthesis mechanism of PMNPs was described in detail
in the previous paper [8], and the successful coating of
poly(MAA-PEGMA) on the Fe3O4 nanoparticles was ascertained
from FT-IR analyses (TEM image-Figure 1). The PMNPs, with
better hydrophilicity and carboxyl functional groups, would be
desirable for the immobilization of mAb.
The amount of immobilized mAb onto PMNPs could be
quantitatively determined, using a typical UV spectrum profile
of mAb solution, pre-and post-immobilization and the washing
buffer. As can be seen from Figure 2, the mAb had mostly
immobilized on the PMNPs. Herein, 20 µg of antibody was
immobilized on 1.0 mg of PMNPs with high immobilizing
efficiency.Figure 1: Transmission electron microscopy of the PMNPs.
Figure 2: The UV spectra of pre- and post-immobilization and washing buffer
of monoclonal antibody solution.
3.2. Optimization of immunoassay conditions
In the present method, the HRP-mAb dilution and im-
munoreaction time would be expected to affect the sensibil-
ity and linear range of the method. In order to determine the
optimal antibody dilution, the mAb-PMNPs complex was in-
cubated with three samples of IL-6 with different concentra-
tions (IL-6 concentration was 0, 20, 1000 pg mL−1, designated
as S0, S1, S2, respectively) for 60 min, followed by addition
of 50 µL of serial diluted HRP-mAb, and reacted for another
60 min. The TMB was then added, incubated for 5 min and
stopped by H2SO4. The A450 was read after magnetic separa-
tion, and the result is shown in Figure 3. Although the A450 of
S1 and S2 increased with the decrease in the HRP-mAb dilution
ratio in the examined range of 1:6000–1:500, the A450 of S0
also increased, whichmay lower the sensitivity. So, the effect of
HRP-Ab dilution ratios on A450S1/A450S0 and A450S2/A450S0,
which could indicate the sensitivity and linear range of the as-
say [9], were studied in this experiment. It can be seen from
Figure 3 that the HRP-mAb dilution ratio of 1:1000 and 1:2000
had a wider linear range (the higher A450S2/A450S0) and
higher sensitivity (the higher A450S1/A450S0). By taking into
consideration the importance of the linear range width of the
proposed method and reagent consumption, the dilution of
1:2000 was appropriate. Herein, 1:2000 was selected for fur-
ther study.
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Figure 4: Effect of immunoreaction time.
In order to determine the optimal reaction time, absorbance
at 450 nm was measured after IL-6 standard (400 pg mL−1)
solution was reacted with captured mAb and HRP-mAb
(dilution of 1:2000) in two incubation processes for different
times. The result is shown in Figure 4. The absorbance increased
with immunoreaction times between 0 and 20 min and
then leveled off. This indicates that the interaction between
this antigen and antibody in the homogeneously dispersed
medium reached equilibrium statewithin 20min. Therefore, an
immunoreaction time of 20 min was selected throughout the
experiments.
3.3. Linear range and sensitivity
A calibration plot of the PMNPs-based immunoassaymethod
was performed under optimized conditions. The regression
curve for determination of IL-6 is shown in Figure 5. The linear
range for this assaywas 3.2–1000 pgmL−1 (R = 0.998), and the
lower detection limit of this assay, defined as the concentration
at the means +3 SD of the 20 determination of the zero
calibrator, was 1.0 pg mL−1.
3.4. Precision and recovery
Low, mid and high concentrations of IL-6 standard were
selected to validate the precision of this method. The intra-
assay precision was determined by measuring 10 sets ofFigure 5: Standard curve for IL-6 standards (each point represents the mean of
three values).
Table 1: The CVs for intra- and inter-assay of different concentration of IL-6.
Sample (pg ml−1) SD CV (%) n
Intra-assay
20 0.014 3.16 10
400 0.042 2.14 10
1000 0.048 1.04 10
Inter-assay
20 0.017 6.38 5
400 0.051 3.87 5
1000 0.048 3.27 5
standard solution in a single run, and inter-assay precision
was determined in 5 separate assays; each assay measured in
5 sets. The Coefficients of Variation (CVs) for intra-assay and
inter-assay were 1.04%–3.16% and 3.27%–6.38%, respectively
(Table 1).
Recovery was assessed by adding 20 µL of standard IL-6,
appropriately diluted to 80 µL of serum samples and analyzing
the spiked and unspiked samples. The percent recovery of IL-6
was determined by comparison of the added amount of IL-6 to
the amount measured after subtracting the endogenous levels.
As shown in Table 2, IL-6 recovery, added at low, mid, and high
concentrations (20, 400 and 1000 pg mL−1), was 91.0%–97.8%.
This result demonstrated that the PMNPs-based immunoassay
could be a useful assay in accurately detecting IL-6 in serum.
3.5. Detection of IL-6 concentration in serum samples
The feasibility of the PMNPs-based immunoassay system
for possible clinical applications was investigated by analyzing
several samples in comparison with the conventional ELISA
method. These serum samples were diluted to different
concentrations with a phosphate buffer solution of pH 7.0.
Figure 6 describes the correlation between the results obtained
by the PMNPs-based immunoassay and by the conventional
ELISA method. The regression equation obtained is y =
0.996x− 1.437, with a correlation coefficient of 0.993. It
obviously indicates that this new method may provide a
feasible alternative tool for determining IL-6 in human serum
in clinical laboratories.
A total of 8 serum samples frompatientswith hepatocellular
carcinoma (HCC), and 9 from normal healthy controls, were
analyzed for IL-6 concentration. As illustrated in Figure 7, the
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Standard IL-6 added (pg ml−1) IL-6 endogenous levels (pg ml−1) Theoretical IL-6 value (pg ml−1) Measured value (pg ml−1) Recovery (%)
20 46.8 56.8 55.9 91.0
400 46.8 446.8 424.0 94.3
1000 46.8 1046.8 1013.4 96.7Figure 6: Comparison of the titer results of determining samples between the
conventional ELISA and the PMNPs-based immunoassay.
Figure 7: Serum levels of interleukin-6 in hepatocellular carcinoma (HCC)
patients and normal controls.
serum IL-6 values ranged from 5.2 to 14.2 pg mL−1 in all 11
normal controls. However, the median IL-6 concentration in
patients with HCC, 135.7 pgmL−1 (range 16.2–548.0 pgmL−1),
was significantly higher than normal controls. It is known that
IL-6 is produced by various normal and tumorigenic human
cells, and plays an important role in the pathophysiological
processes of viral, autoimmune andother immunedisorders [4].
Most patients with HCC have evidence of viral infections such
asHBV andHCV [10]. So, IL-6was expressed highly in hepatoma
cells.
4. Conclusion
In summary, we have developed a simple and rapid
quantitative immunoassay method for detection of IL-6, based
on PMNPs. This assay shows high intra-assay precision (CVs isless than 4%) and inter-assay procession (CVs is less than 8%).
The recovery of IL-6 ranged from 91.0% to 97.8%. The PMNP-
based method reduces the time of the process, and there is
no significant difference compared with conventional ELISA;
it provides potential application to immunological research
and clinical testing in the future. The same method can be
potentially used in detection of a broad range of biomolecules
in a rapid, precise and accurate way.
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